HCV Advocate LogoHCV Advocate Logo
Contact Us Site Map Resources en Espanol
For living Positivley. Being Well
About Hepatitis
News Updates
News Review
Conference reports
News Articles
HCV Advocate Newsletter
Sign up for Email Updates
Community & Support
Resource Library
About Hcsp
 
Bookmark and Share
News Review

Top News
from EASL 2011

 

  EASL 2011 Peregrine Presents Phase Ib HCV/HIV Data on Single-Agent Bavituximab at EASL
Apr 4

  EASL 2011 Abbott and Enanta Present Positive 12-Week Results and 3-Day Resistance Data From Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
Apr 4

  EASL 2011 Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment
Apr 3

  EASL 2011 Boehringer Ingelheim’s lead hepatitis C compound moves into phase III – the first within the BI HCV portfolio:
FDA Fast Track designations granted for both: the protease inhibitor BI 201335 plus standard-of-care and the interferon-free combination of BI 201335 with polymerase inhibitor, BI 207127

Apr 2

  EASL 2011 PegIFN-lambda shows superior virological response and improved safety than PegIFN-alpha-2a
Apr 2

  EASL 2011 Idera Pharmaceuticals Presents Data from a Phase 1 Clinical Trial of IMO-2125 in Treatment-Naïve Genotype 1 HCV Patients atEASL 2011
Apr 2

  EASL 2011 New Data Analyses with VICTRELIS™ (boceprevir), Merck's Investigational Medicine, Examined Possible Predictors of Sustained Virologic Response
Apr 1

  EASL 2011 First Vaccine For Viral Hepatitis C Could Become A Reality
Apr 1

  EASL 2011 Conatus Pharmaceuticals Presents Results From a Phase 2 Clinical Trial of CTS-1027 in HCV Genotype 1 Null-Responders
Apr 1

  EASL 2011 Positive Phase 2 Results Reported with Boehringer Ingelheim's Investigational HCV Protease Inhibitor in Both Previously Treated and Untreated Patients
Apr 1

  EASL 2011 Medivir: Week 24 Interim Results From TMC435 Hepatitis C Phase 2b ASPIRE Study Presented at EASL
Apr 1

  EASL 2011 OctoPlus' licensee Biolex presents Phase IIb results at EASL showing reduced rates of depression in HCV patients treated with Locteron
Mar 31

  EASL 2011 Fluvastatin Enhances Chronic Hepatitis C Treatment Response in Combination with Pegylated Interferon-Alpha and Ribavirin
Mar 31

  EASL 2011 Novartis first-in-class antiviral DEB025 achieved sustained viral response in 76% of patients with chronic hepatitis C, new phase II study shows
Mar 31

 

 


About Hepatitis | News Updates | Community & Support | Resource Library | About HCSP | Contact Us | Site Map | Recursos en Español | Home

Hepatitis C Support Project

© 2011 Hepatitis C Support Project

Medical  Writers' Circle
Fact Sheets